Patrick Campbell

Approval of isatuximab-irfc (Sarclisa) was based on the results of a 307-person trial, according to a statement from the FDA.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

Sika Dunyoh, director of education programs with NORD, discusses that year in rare disease and what to expect moving forward.

A new study examines how different types of chronic conditions were associated with different increases in risk of visual impairment.

A discussion on how to approach the real-world application of bempedoic acid with the Chief of Cardiology at Baylor College of Medicine.

The non-statin, fixed-dose combination therapy received approval less than one week after bempedoic acid received approval for treatment of HeFH.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

Early menopause onset has been linked to increased CVD risk, but a new study from England is examining whether age of onset has a role in worsening risk factors.

The VistaScan mobile ultrasound platform from Emagine Solutions Technology can be used via an app and connect directly to a clinician's cell phone or tablet.

Results of the LINK-HF study indicate a wearable sensors from Vital Connect combined with a predictive algorithm can predict HF exacerbations.

The FDA announced the first approval of ProAir HFA—1 of the most popular inhalers in the US market.

New data from a study of 30 patients found specific characteristics of gut microbiota could predict the presence of pulmonary hypertension with greater than 80% accuracy.

With approval, the GLP-1 receptor agonist becomes the first diabetes drug approved for reducing MACE in patients with and without established cardiovascular.

The approval of bempedoic acid (Nexletol) marks the first oral, non-statin therapy approved by the FDA as a lipid-lowering agent in nearly 20 years.

The Novalung System is the first ECMO device approved for use for more than 6 hours.

Clinical trial data for the lipid-lowering non-statin agent indicates it can lower LDL-C by as much as 18% when combined with maximally tolerated statins.

A secondary analysis of patients with prior stroke, TIA, or thromboembolism from AUGUSTUS is revealing more about the use of apixaban in patients with AFib.

New data indicates a combination of 3 natural extracts added to standard therapy could provide benefits in patients with uncontrolled hypertension.

An analysis of the French cohort from the TST trial was presented during ISC 2020 in Los Angeles, CA.

Research from the Karolinska Institute indicates ESC/EAS 2019 dyslipidemia guidelines could create an unforeseen financial burden due to new eligibility for PSCK9 class.

Macrolide use during the first trimester was linked to an increase in major malformations—specifically cardiovascular malformations—in children.

A fourth-year medical student keeps a log of the sessions he attends and his perspective on information from the SCCM's 49th Annual Critical Care Congress.

A new analysis is revealing more about how using a patient portal can aid in medication adherence and HbA1c management among diabetics.

New data on the use of polygenic risk scores for predicting certain forms of cardiovascular disease raise questions about the validity of genetic scores in real-world settings.

Analysis using data from the Nurses' Health Study is shedding new light on the interaction of TMAO and coronary heart disease risk.

A new study from the Columbia University Irving Medical Center found another diuretic appeared to have less serious side effects than the guideline-recommended chlorthalidone.

The FDA announced the switch of the 2 eyedrops, which took place through their RX-to-OTC program.

A study from Rutgers University is shedding more light on the additional cardiovascular risk among preeclamptic women.

Vitreoretinal surgeon discusses what ophthalmologists would need to see from a new treatment to replace aflibercept as first-line treatment for wet AMD.